Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CSF diazepam-binding inhibitor concentrations in panic disorder.

R Payeur1, R B Lydiard, J C Ballenger

  • 1Medical University of South Carolina, Department of Psychiatry, Charleston 29425.

Biological Psychiatry
|October 15, 1992
PubMed
Summary

Diazepam-binding inhibitor (DBI) levels in cerebrospinal fluid (CSF) did not differ between panic disorder patients and controls. However, panic patients showed a positive correlation between CSF DBI and corticotropin-releasing hormone (CRH).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From the benches to the trenches : training residents to provide emergency outreach services-a public/academic project.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
Same author

Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies.

Postgraduate medicine·2009
Same author

Novel treatments for major depressive disorder.

CNS spectrums·2009
Same author

Vagus nerve stimulation: a new form of therapeutic brain stimulation.

CNS spectrums·2008
Same author

Consensus statement on depression, anxiety, and cardiovascular disease.

The Journal of clinical psychiatry·2002
Same author

Irritable bowel syndrome, anxiety, and depression: what are the links?

The Journal of clinical psychiatry·2002

Area of Science:

  • Neuroscience
  • Psychiatry
  • Endocrinology

Background:

  • Diazepam-binding inhibitor (DBI) is a neuropeptide found in the brain and CSF.
  • DBI may act as an endogenous anxiogenic ligand, influencing GABAergic transmission at the benzodiazepine-GABA receptor complex.
  • Previous research suggests a potential role for DBI in anxiety modulation.

Purpose of the Study:

  • To measure DBI immunoreactivity (DBI-IR) in the CSF of panic disorder patients and normal controls.
  • To investigate potential differences in CSF DBI concentrations between these groups.
  • To explore correlations between CSF DBI levels and other neurochemicals, including corticotropin-releasing hormone (CRH).

Main Methods:

  • Lumbar CSF samples were collected from 18 panic disorder patients and 9 healthy volunteers.

Related Experiment Videos

  • DBI immunoreactivity (DBI-IR) was quantified in CSF using immunoassay techniques.
  • Statistical analyses were performed to compare DBI-IR levels and assess correlations with other neurochemicals.

    • Main Results:

    • No significant differences in CSF DBI-IR concentrations were found between panic disorder patients (1.12 +/- 0.27 pmol/mL) and normal controls (1.23 +/- 0.27 pmol/mL).
    • No significant gender-related differences in CSF DBI-IR levels were observed.
    • A positive correlation was identified between CSF DBI levels and CSF CRH concentrations in panic disorder patients.

    Conclusions:

    • CSF DBI-IR levels do not appear to be significantly altered in panic disorder patients as a group.
    • The positive correlation between CSF DBI and CRH in panic patients suggests a potential neuroendocrine link in the disorder.
    • Further research is warranted to elucidate the functional significance of the DBI-CRH interaction in panic disorder pathophysiology.